Factor VIII Antigen, Activity, and Mutations in Hemophilia A

Clin Appl Thromb Hemost. 2016 May;22(4):381-5. doi: 10.1177/1076029614562951. Epub 2014 Dec 29.

Abstract

Factor VIII (FVIII) activity, antigen, and its gene mutation in patients may give us some insight into structure-activity relationship and probable reason for its low level in a particular patient. A total of 53 cases with hemophilia A and 17 normal individuals were analyzed for

Fviii: C and

Fviii: Ag levels along with their blood groups to determine their cross-reacting material (CRM) status. In all, 37 cases (18 moderate and 19 mild) were found to have discordant CRM status. Missense mutations (Ala723ThrandLys439Ser) and protein truncating changes (Trp1854*andArg2326*) were observed in 2 each of these cases. Although 37 (70%) of the 53 had discordant antigen-activity ratio, majority of those mutations produced FVIII with low FVIII-specific activity. However, 4 (7.5%) of the 53 mutations produced higher specific activity of FVIII. It is possible that these mutations either produce a secretory defect or an increased metabolic turnover to account for the low levels of FVIII with these mutations.

Keywords: cross-reacting material; hemophilia A; mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Codon, Nonsense*
  • Factor VIII* / genetics
  • Factor VIII* / metabolism
  • Hemophilia A* / blood
  • Hemophilia A* / genetics
  • Humans
  • Male
  • Mutation, Missense*

Substances

  • Codon, Nonsense
  • F8 protein, human
  • Factor VIII